Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01887288 · ClinicalTrials.gov registry record · Phase 2

Capecitabine With Digoxin for Metastatic Breast Cancer

A Phase 2 study, sponsored by Western Regional Medical Center.

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT01887288: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.

NCT01887288 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01887288, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

Primary Outcome

Evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

Interventions

  • DRUG Capecitabine
  • DRUG Digoxin

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-04
Est. Completion 2015-11
Phase Phase 2
Western Regional Medical Center

17 total trials

Why NCT01887288 stopped before completion

NCT01887288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.

NCT01887288 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01887288 about?

NCT01887288 is a clinical study titled "Capecitabine With Digoxin for Metastatic Breast Cancer". To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

What is the current status of trial NCT01887288?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-04. Estimated completion is 2015-11.

What interventions are being tested in trial NCT01887288?

The interventions under investigation include: Capecitabine (DRUG), Digoxin (DRUG).

Who is sponsoring clinical trial NCT01887288?

This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01887288's enrollment target sits among peer trials

16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01887288, the US trial registry maintained by the National Library of Medicine. NCT01887288 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.